News
Project news, updates, and announcements.
iThera Webinar: Optoacoustics and Optical: Complementary Modalities for Molecular Imaging
Both optoacoustic and optical imaging are biophotonic imaging technologies. While optoacoustic imaging yields information about light absorption from both endogenous tissue chromophores and optical contrast agents, optical imaging only provides information from extrinsically administered agents by means of light emission (fluorescence or bioluminescence). In terms of performance, optical imaging can serve as an easy-to-use screening tool with limited resolution and depth penetration, while optoacoustic imaging can probe biological questions in more detail and at greater depth. In this webinar, hear 10-minute presentations from three leading scientists who utilize both complementary imaging methods to study diseases on a molecular level, across three different applications:
- Cancer: Judith Weber PhD, University of Cambridge
- Inflammation: Alexa Hasenbach, University of Münster
- Diabetes: Dr Sheryl Roberts, Memorial Sloan Kettering
iThera Medical’s upcoming webinar on May 20, 2020, will take place at 3:00 PM BST/ 4:00 PM CEST / 10:00 AM EDT. Sign up here.
EUPHORIA joins EU-funded New Deal for live Twitter chat to explore the future of IBD treatment
Professor Dr Max Waldner of University Hospital Erlangen participated in a live Twitter chat on Monday, April 27, 2020.
The chat was hosted by Bruno Martin of ScienSeed, a partner on the New Deal, an EU Horizon 2020 funded project and one of EUPHORIA’s “Related Projects“. Joining Max and Bruno was Dr Azucena Salas, a researcher at IDIBAPS in Barcelona and principal investigator on the New Deal project, and Rachel Sawyer, a UK-based IBD patient advocate who manages the successful online Twitter stream, @bottomline_ibd.
The 50-minute chat focused on the state of the art and future prospects for IBD research, treatment and management. Watch it here!
Max remarked: “There is real value in communicating in a multi-disciplinary live forum such as this. It was a pleasure to be involved and to provide information about EUPHORIA with the public in this way. We will continue to share knowledge and build bridges with others working in research and patient advocates to improve IBD treatment.”
EUPHORIA explainer film is launched!
EUPHORIA coordinators at iThera Medical Gmbh have produced a short explainer film to showcase the emerging diagnostic imaging technology, Multispectral Optoacoustic Tomography or MSOT for monitoring and managing inflammatory bowel disease. Watch it here https://youtu.be/dk8ioq9oG6I
Since 2010, iThera Medical has been selling successfully worldwide into the pre-clinical research imaging market. iThera Medical has established a global distribution network for its pre-clinical systems. EUPHORIA is a key enabling step for iThera to enter the clinical imaging market.
iThera Medical has a highly experienced team of currently 34 employees with expertise covering all aspects of optoacoustic technology, e.g., laser physics and fiberoptic light guides, data acquisition electronics, ultrasound detector design, and general electronic, electrical and mechanical capabilities.
EUPHORIA has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 830965. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.
EUPHORIA at Meeting in Besancon
The EUPHORIA team enjoyed a very productive meeting in Besancon, France last week. The meeting ran over 2 days (23 and 24 January 2020) and all the partners were represented.
Researchers presented updates on all workstreams. IMASONIC and iThera outlined the significant progress made on improving the probe and transducer for the MSOT device. Final testing of the prototypes will be completed shortly and the choice of the transducer for use in the trial will be confirmed. Testing to date shows significant improvements. Software tasks in WP3 (led by Rayfos) are also well advanced.
Now that the EUPHORIA study protocol is near-final, work in WP4 by iThera and UK Erlangen is focused on preparations for the trial and obtaining ethical approval. Plans were discussed for a study workshop with the Advisory Board in February.
Preliminary work on certification of the device has already commenced in WP5 and dissemination and communication activities continue, with the new project video due for release shortly.
By the end of the meeting, the partners had agreed to a plan for the busy months ahead. Many thanks to our hosts in IMASONIC for a very fruitful and enjoyable event!
New EUPHORIA Dissemination tool available for use
We have created a EUPHORIA concept slide to facilitate dissemination efforts for our partners.
You can download the slide and our promotional brochure on our Promotional Materials page https://euphoria2020.eu/promotional-materials/.
EUPHORIA-acknowledged paper published in Nature Medicine, 2 December 2019
EUPHORIA exhibited by iThera at 43. Dreiländertreffen der DEGUM, ÖGUM und SGUM
EUPHORIA Coordinators iThera Medical GmbH Biomedizinische Bildgebung exhibited at the 43. Dreiländertreffen der DEGUM, ÖGUM und SGUM in Leipzig, Germany. The ultrasound meeting, Ultraschall 2019, ran from October 16th-19th, 2019. There was a dedicated session to IBD (aka CED in German). EUPHORIA brochures were available at iThera’s booth, F32 where iThera Medical‘s CEO Christian Wiest (pictured below) was on hand to explain their MSOT technologies and EUPHORIA’s Fast-Track-to-Innovation plans.
According to this year’s congress motto “Shaping the present and the future with ultrasound”, the focus of the congress was on practical training in theory and practice as well as in the translation of the latest scientific findings.
See the meeting programme (in German) below or here.
